Acasti Announces Court Dismissal of Stockholder Litigation :

LAVAL, Québec, Sept. 30, 2022 -- Acasti Pharma Inc. , a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases,... | September 30, 2022

Related Keywords

New York , United States , Canada , Canadian , Katherine Polk Failla , Robert Blum , Jan Dalvise , Company Nasdaq , United States District Court , Exchange Commission , Acasti Pharma Inc , Lytham Partners , Securities Exchange , Grace Therapeutics Inc , Regulation Services Provider , Us Securities Exchange , Grace Therapeutics , Exchange Act , Judge Katherine Polk Failla , Southern District , Judge Failla , Orphan Drug Designation , Subarachnoid Hemorrhage , Postherpetic Neuralgia , Securities Litigation Reform Act , Securities Act , Securities Exchange Act , Acasti Pharma Inc Stock Exchange , News , Information , Press Release , 022 , Ancasti , Dharma , Specialty , Company , Dvancing , Three , Linical , Stage , Drug , Candidates , Ddressing , Mare , End , Rphan Acst Ca00430k8730 ,